Are you a healthcare Professional?

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

No Yes

For US Healthcare Professionals

MENU
CLOSE

Evidence-based.
Estrogen-free.

Estroven® Complete Multi-Symptom offers safe, effective, naturally sourced relief for every stage of menopause*

Hormonal therapy isn’t the only path to menopause relief

Menopause is a natural part of life—and hot flashes are the most common complaint, affecting up to 3 out of 4 women.1 Peri- and postmenopausal women may also experience vaginal dryness, weight gain, bladder issues, and changes in sleep, mood, and memory.1

Hormone therapy is commonly prescribed to relieve these symptoms, even for women still menstruating. While effective, it carries increased risks of breast cancer, uterine cancer, and blood clots.2,3

When hormone therapy isn’t feasible, certain antidepressants, antiepileptics, or antihypertensives may be used to manage hot flashes.1 However, these alternatives often don’t provide comprehensive relief and may cause side effects.4 As a result, many peri- and postmenopausal women seek safe, effective alternatives.

Estroven Complete Multi-System packaging.

Extracted from nature.
Rooted in science.

Estroven® Complete Multi-Symptom Menopause Relief is formulated with rhapontic rhubarb—a non-hormonal, naturally sourced extract clinically proven to safely relieve menopause symptoms.*

Rhapontic rhubarb is shown to relieve all symptoms tested*† per the Menopause Rating Scale (MRS)2:

Reduce hot flashes
& night sweats*

Support
restful sleep*

Manage daily
stress & mood*

Reduce physical
& mental exhaustion*

Promote
concentration*

Promote joint
& muscular comfort*

Manage menopausal
anxiety*

Support urinary
& bladder health*

Manage
vaginal dryness*

Support
libido*

How rhapontic rhubarb root extract works for menopause*

Rhapontic rhubarb root extract has been shown to selectively activate estrogen receptor beta (ERβ)—a mechanism that helps alleviate menopausal symptoms while supporting a favorable safety profile.5,6

In vitro studies revealed 2 key findings: First, rhapontic rhubarb root extract activated ERβ in both endometrial and bone cell models, and this effect was blocked by an antiestrogen agent. Second, it produced only minimal stimulation of estrogen receptor alpha (ERα) in the bone model. These results demonstrate ERβ selectivity.6

Although rhapontic rhubarb root extract is not a selective estrogen receptor modulator (SERM), it selectively activates ERβ similar to some of the SERMs.

Estrogen Receptor Subtype Selectivity

Slide to see how rhapontic rhubarb root extract works

Estrogen (Estradiol)

Rhapontic Rhubarb
Root Extract



ERα receptor.
ERβ receptor.

Hormone replacement therapy targets both ERα and ERβ. Due to the actions in their targeted tissues and organ systems, menopausal women taking them may be at an increased risk of breast and uterine cancers along with increased blood clotting and strokes.7

Selective estrogen receptor modulators, or SERMs, activate or block estrogen receptors in certain areas of the body and can be used to prevent and/or treat breast cancer, osteoporosis, and vaginal thinning/dryness due to menopause.7,8

Rhapontic rhubarb root extract exerts its effect selectively on ERβ receptors, similar to the way some SERMs work, to help treat menopause symptoms.8

Slide to see how rhapontic rhubarb root extract works

Clinically proven to safely relieve multiple menopause symptoms*

Clinical studies for rhapontic rhubarb

28 days


12 weeks


6 months


2 years



Significantly reduced all menopause symptoms in 28 days2

  • After 28 days of rhapontic rhubarb extract supplementation, a statistically significant reduction in total menopause symptoms was demonstrated
  • After 84 days there was a 60% reduction compared to baseline with no change in the placebo group

Significantly Improved Total Menopause Symptom Scores

Chart showing the total menopause rating scale (MRSII) score comparing rhapontic rhubarb extract vs placebo and highlighting a 60% reduction in total menopause symptoms with rhapontic rhubarb extract. Chart showing the total menopause rating scale (MRSII) score comparing rhapontic rhubarb extract vs placebo and highlighting a 60% reduction in total menopause symptoms with rhapontic rhubarb extract. Chart showing the total menopause rating scale (MRSII) score comparing rhapontic rhubarb extract vs placebo and highlighting a 60% reduction in total menopause symptoms with rhapontic rhubarb extract.

Study Design

A 12-week, randomized, placebo-controlled study evaluated the effects of rhapontic rhubarb root extract compared with placebo in 109 perimenopausal women.2

  • 83.3% of women taking rhapontic rhubarb experienced significant improvement in all symptoms vs 1.8% of women on placebo
  • A 90% reduction in hot flashes was observed by week 12
  • Rhapontic rhubarb extract was well tolerated with no safety concerns identified

12-Week Study of
Rhapontic Rhubarb Root Extract vs Placebo:
Reduction in Hot Flashes

Chart showing the hot flash weekly weighted score comparing the placebo with rhapontic rhubarb root extract, which showed a 90% reduction in hot flashes at 12 weeks. Chart showing the hot flash weekly weighted score comparing the placebo with rhapontic rhubarb root extract, which showed a 90% reduction in hot flashes at 12 weeks.

Long-term studies confirm safety and sustained symptom relief

Two long-term observational studies were conducted to evaluate the safety and effectiveness of rhapontic rhubarb root extract.9,10

Six-Month Study (n=252)10:

  • Included both perimenopausal and postmenopausal women
  • Showed significant reductions across all symptoms on the Menopause Rating Scale (MRS II)
  • 90% of women rated the extract's tolerability as good or very good
  • No safety concerns were reported

Six-Month Study of Rhapontic Rhubarb Root Extract:
Menopause Rating Scale Scores

Chart comparing various menopause symptoms from the study start to the final assessment after 6 months.
Swipe
for more


Chart comparing various menopause symptoms from the study start to the final assessment after 6 months.

Long-term studies confirm safety and sustained symptom relief

Two long-term observational studies were conducted to evaluate the safety and effectiveness of rhapontic rhubarb root extract.9,10

Two-Year Follow-Up Study9:

  • Enrolled participants from the original 12-week placebo-controlled study
  • Tracked outcomes over a total of 2 years (including the original study duration)
  • By 48 weeks, symptom scores decreased by 83% and remained stable through the end of the study
  • Rhapontic rhubarb root extract was well tolerated and no side effects from its use were noted

Two Year-Long Study Demonstrated Safety & Efficacy

Chart comparing menopause rating scale (MRS II) scores between rhapontic rhubarb extract, placebo until week 12, and placebo group switched to rhapontic rhubarb extract after week 12. Chart comparing menopause rating scale (MRS II) scores between rhapontic rhubarb extract, placebo until week 12, and placebo group switched to rhapontic rhubarb extract after week 12. Chart comparing menopause rating scale (MRS II) scores between rhapontic rhubarb extract, placebo until week 12, and placebo group switched to rhapontic rhubarb extract after week 12.

Ready to offer relief without hormones?

Recommend Estroven® Complete Multi-Symptom Menopause Relief
as a safe, effective option for menopausal patients seeking
relief beyond hormones.

Request Coupons

By clicking Request Coupons, you're confirming that you agree with our Terms and Conditions.

*THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE OR PREVENT ANY DISEASE.

†Based on a clinical study after 12 weeks of use.

References:

  1. Menopause Symptoms and Relief. U.S. Department of Health & Human Services, Office on Women's Health. Updated May 22, 2018. Accessed July 29, 2025. https://www.womenshealth.gov/menopause/menopause-symptoms-and-relief
  2. Heger M, Ventskovskiy BM, Borzenko I, Kneis KC, Rettenberger R, Kaszkin-Bettag M. Open, randomized, parallel-group study of the clinical efficacy of a rhapontic rhubarb root extract in perimenopausal women with climacteric complaints. Menopause. 2006;13(5):744–759.
  3. Vollmer G, Papke A, Zierau O. Lignan and isoflavone phytoestrogens—alternatives to hormone replacement therapy? Chin Med. 2010;5:7. doi:10.1186/1749-8546-5-7
  4. Huang AJ, Faubion S, Grady D. Nonhormonal treatment of menopausal vasomotor symptoms. JAMA Intern Med. 2025;185(7):874-875. doi:10.1001/jamainternmed.2025.0990
  5. Möller F, Zierau O, Jandausch A, Rettenberger R, Kaszkin-Bettag M, Vollmer G. Subtype-specific activation of estrogen receptors by a special extract of Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds in U2OS human osteosarcoma cells. Phytomedicine. 2007;14(11):716-726. doi:10.1016/j.phymed.2007.09.001
  6. Papke A, Kretzschmar G, Zierau O, Kaszkin-Bettag M, Vollmer G. Effects of the special extract ERr 731 from Rheum rhaponticum on estrogen-regulated targets in the uterotrophy model of ovariectomized rats. J Steroid Biochem Mol Biol. 2009;117(4-5):176-184. doi:10.1016/j.jsbmb.2009.09.011
  7. Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. Steroids. 2014;90:13-29. doi:10.1016/j.steroids.2014.06.012
  8. Vollmer G, Papke A, Zierau O. Treatment of menopausal symptoms by an extract from the roots of rhapontic rhubarb: the role of estrogen receptors. Chin Med. 2010;5:7. doi:10.1186/1749-8546-5-7
  9. Hasper I, Ventskovskiy BM, Rettenberger R, Heger PW, Riley DS, Kaszkin-Bettag M. Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms. Menopause. 2009;16(1):117-131. doi:10.1097/GME.0b013e3181806446
  10. Kaszkin-Bettag M, Beck S, Richardson A, Heger PW, Beer AM. Efficacy of the special extract ERr 731 from rhapontic rhubarb for menopausal complaints: a 6-month open observational study. Altern Ther Health Med. 2008;14(6):32-38.

© 2025 dsm-firmenich group – All rights reserved.

Use of this site signifies your agreement to the Terms of Use. View our Privacy Policy.